[HTML][HTML] Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine
…, KA Swanson, S Roychoudhury, K Koury… - New England journal …, 2020 - Mass Medical Soc
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and
the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in …
the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in …
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
…, M Shiffman, R Reindollar, ZD Goodman, K Koury… - The Lancet, 2001 - thelancet.com
Background A sustained virological response (SVR) rate of 41% has been achieved with
interferon alfa-2b plus ribavirin therapy of chronic hepatitis C. In this randomised trial, …
interferon alfa-2b plus ribavirin therapy of chronic hepatitis C. In this randomised trial, …
[HTML][HTML] Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months
…, X Xu, S Roychoudhury, K Koury… - … England Journal of …, 2021 - Mass Medical Soc
Background BNT162b2 is a lipid nanoparticle–formulated, nucleoside-modified RNA vaccine
encoding a prefusion-stabilized, membrane-anchored severe acute respiratory syndrome …
encoding a prefusion-stabilized, membrane-anchored severe acute respiratory syndrome …
[HTML][HTML] Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates
…, R Bailey, KA Swanson, P Li, K Koury… - … England Journal of …, 2020 - Mass Medical Soc
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections
and the resulting disease, coronavirus disease 2019 (Covid-19), have spread to millions of …
and the resulting disease, coronavirus disease 2019 (Covid-19), have spread to millions of …
[HTML][HTML] Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age
…, KA Swanson, H Ma, X Xu, K Koury… - … England Journal of …, 2022 - Mass Medical Soc
Background Safe, effective vaccines against coronavirus disease 2019 (Covid-19) are urgently
needed in children younger than 12 years of age. Methods A phase 1, dose-finding study …
needed in children younger than 12 years of age. Methods A phase 1, dose-finding study …
[HTML][HTML] Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants
…, M Duron Padilla, PC Richmond, K Koury… - … England Journal of …, 2023 - Mass Medical Soc
Background Whether vaccination during pregnancy could reduce the burden of respiratory
syncytial virus (RSV)–associated lower respiratory tract illness in newborns and infants is …
syncytial virus (RSV)–associated lower respiratory tract illness in newborns and infants is …
[HTML][HTML] Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents
…, KA Swanson, H Ma, X Xu, K Koury… - … England Journal of …, 2021 - Mass Medical Soc
Background Until very recently, vaccines against severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) had not been authorized for emergency use in persons younger than …
2 (SARS-CoV-2) had not been authorized for emergency use in persons younger than …
[HTML][HTML] Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection
…, MN Davis, P Mukhopadhyay, K Koury… - … England Journal of …, 2009 - Mass Medical Soc
Background Treatment guidelines recommend the use of peginterferon alfa-2b or
peginterferon alfa-2a in combination with ribavirin for chronic hepatitis C virus (HCV) infection. …
peginterferon alfa-2a in combination with ribavirin for chronic hepatitis C virus (HCV) infection. …
[HTML][HTML] Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults
…, K Schneider, D Cooper, K Koury… - … England Journal of …, 2023 - Mass Medical Soc
Background Respiratory syncytial virus (RSV) infection causes considerable illness in older
adults. The efficacy and safety of an investigational bivalent RSV prefusion F protein–based (…
adults. The efficacy and safety of an investigational bivalent RSV prefusion F protein–based (…
[HTML][HTML] Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
…, V Raabe, R Bailey, KA Swanson, P Li, K Koury… - Nature, 2020 - nature.com
In March 2020, the World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19),
which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-…
which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-…